UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 21, 2016
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-33451 | | 90-0136863 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
50 Milk Street, 16th Floor Boston, Massachusetts | | 02109 |
| (Address of principal executive offices) | | (Zip Code) |
(857)415-4774
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
On December 21, 2016, Albireo Pharma, Inc. (the “Company”) updated its corporate presentation, which the Company expects to present from time to time and which may be distributed by the Company in hardcopy or electronic form. The updates include preliminary data from the five cohorts completed to date in the Company’s ongoing open label, Phase 2 clinical trial designed to evaluate the efficacy and safety of A4250 in children with chronic cholestasis.
A copy of the Company’s updated corporate presentation is attached as Exhibit 99.1 to this Current Report on Form8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| | |
| |
| 99.1 | | Corporate presentation dated December 21, 2016 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | | ALBIREO PHARMA, INC. |
| | |
| Date: December 21, 2016 | | | | /s/ Ronald H.W. Cooper |
| | | | Ronald H.W. Cooper |
| | | | President and Chief Executive Officer |
2
